Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

By D. Mahalingam, G. Wilding, S. Denmeade, J. Sarantopoulas, D. Cosgrove, J. Cetnar, N. Azad, Justine Yang Bruce, M. Kurman, V. Allgood and 1 more. 2016

Subfields: Drug Discovery, Oncology, Pharmacology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Knebel
2. Maximilian Linxweiler
3. S. Körner
4. L. Brust
5. Matthias Schneider
6. F. Braun
7. S. Wemmert
8. J. Kühn

Citations in the corpus

• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “The first clinical trials that investigated comparable therapeutic strategies in humans showed promising results that need to be confirmed by phase II and III trials [38].”